<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520217</url>
  </required_header>
  <id_info>
    <org_study_id>06919</org_study_id>
    <nct_id>NCT04520217</nct_id>
  </id_info>
  <brief_title>Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects</brief_title>
  <official_title>Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wright State Physicians</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wright State Physicians</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is three-fold. First, researchers will assess whether subjects who&#xD;
      have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of&#xD;
      microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of&#xD;
      skin. Second, researchers will assess if topical application of the medicine imipramine will&#xD;
      block UVB-induced MVP release. Third, researchers will assess if the topical cream will block&#xD;
      UVB-induced increased erythema reactions (reddening of the skin).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microvesicle particle levels from baseline in clinically photosensitive subjects</measure>
    <time_frame>4 Hours</time_frame>
    <description>This will be measured in skin biopsies obtained at 4 hours following ultraviolet B radiation fluence of 1000 J/m2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in microvesicle particle levels from baseline post topical imipramine application</measure>
    <time_frame>4 Hours</time_frame>
    <description>This will be measured in skin biopsies with topical imipramine applied. Biopsies are obtained at 4 hours following ultraviolet B radiation fluence of 1000 J/m2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin erythema from baseline on topical imipramine treated skin</measure>
    <time_frame>4 Hours</time_frame>
    <description>This will be measured with a mexameter at 4 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin erythema from baseline on topical imipramine treated skin</measure>
    <time_frame>24 Hours</time_frame>
    <description>This will be measured with a mexameter at 24 hours.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Photosensitivity</condition>
  <condition>Microvesicle Particle</condition>
  <arm_group>
    <arm_group_label>4% Imipramine Cream on UVB-Treated Areas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.&#xD;
2g of base cream will be applied to the UVB-treated areas on volar forearm and back.&#xD;
No cream will be applied to a UVB-treated area on the back</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4% Imipramine Cream</intervention_name>
    <description>4% Imipramine Cream</description>
    <arm_group_label>4% Imipramine Cream on UVB-Treated Areas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Base Cream</intervention_name>
    <description>Base Cream</description>
    <arm_group_label>4% Imipramine Cream on UVB-Treated Areas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and Male adult subjects age 18 to 50&#xD;
&#xD;
          -  Must be able to give informed consent&#xD;
&#xD;
          -  Have access to stable transportation&#xD;
&#xD;
          -  All skin types on Fitzpatrick Scale (Type I-VI)&#xD;
&#xD;
          -  Self-Identified photosensitivity&#xD;
&#xD;
          -  Able to provide medical history and list of medications-control subjects will not be&#xD;
             allowed to be taking a medication that is known to be photosensitizer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes&#xD;
             mellitus)&#xD;
&#xD;
          -  Taking medications that are known photosensitizers (e.g., doxycycline) or&#xD;
             anti-inflammatories (e.g., NSAIDS [except for low-dose aspirin] or steroids)&#xD;
&#xD;
          -  Utilizing imipramine or any other tricyclic antidepressant (oral or cream)&#xD;
&#xD;
          -  Utilizing topical anti-inflammatory or systemic agents (e.g., prednisone)&#xD;
&#xD;
          -  Large tattoos in the designated testing areas&#xD;
&#xD;
          -  Tanning bed use within last 3 months&#xD;
&#xD;
          -  Photodynamic Therapy or UVB treatments in past 3 months&#xD;
&#xD;
          -  Female Subjects: pregnant or nursing&#xD;
&#xD;
          -  History of abnormal scarring (i.e., keloids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Travers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wright State Physicians Pharmacology Translational Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manager Clinical Research Operations</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regulatory Specialist</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wright State Physicians</investigator_affiliation>
    <investigator_full_name>Jeffrey B. Travers, MD, PhD</investigator_full_name>
    <investigator_title>Chair of Department of Pharmacology and Toxicology and Professor of Dermatology for Boonshoft School of Medicine at Wright State University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

